Check-up: Medicinal cannabis investment puts an energy company in top spot
Health & Biotech
Link copied to
The best-performing health or biotech company in the past fortnight is… an energy company?
BPH Energy (ASX:BPH) describes itself as a diversified business holding investments in biotechnology and resources. In late August, it decided to dip its toes into the medicinal cannabis sector, citing recent legalisation of the drug in Canada and the UK as justifications for the strategy.
The company has made an initial 10 per cent investment in Chilean company Patagonia Genetics, with the option to increase its holding to 49 per cent.
Its shares have risen 100 per cent, albeit from just 0.1c, to 0.2c
News today from Antisense Therapeutics (ASX:ANP) that early preliminary data from the phase II trial of its drug ATL1102 was positive has moved its share price significantly, up 87 per cent to 8.8c.
The drug is testing efficacy against duchenne muscular dystrophy. It is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients, currently treated with corticosteroids.
And Alcidion (ASX:ALC) has also been on the move, up 42 per cent to 23.5c on a partnership with private Australian healthcare provider Healthscope.
At the other end of the scale, G Medical (ASX:GMV) has fallen 33 per cent to 8.1c. It has been in a trading halt, pending a response to an ASX query, since September 6.
Here are all 135 ASX small cap health and biotech stocks and their performance in the past fortnight:
Swipe or scroll to reveal the full table. Click headings to sort